# EU Regulator Recommends Novo’s Wegovy for Obesity-Related Heart Condition – The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) supports the use of Novo Nordisk’s Wegovy for an obesity-related heart condition. – Wegovy, also known as semaglutide, is already approved in the EU and the U.S. for weight management in adults with obesity or who are overweight with weight-related conditions. – The CHMP’s positive opinion will now be reviewed by the European Commission to issue a final decision on the medication’s approval for this specific heart condition. – Novo Nordisk’s Wegovy has shown significant efficacy in helping patients achieve weight loss and manage various weight-related health issues. ### Novo Nordisk’s Wegovy is paving the way for effective weight management solutions, especially for individuals struggling with obesity-related heart conditions. The EMA’s support signifies a step forward in providing patients with innovative treatments for their health needs. Contact Mindful Evolution at https://yourmindfulevolution.com or call or text us at 954-639-9960 for personalized telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. Weight loss disclaimer: Individual results may vary.